AbbVie and Pfizer return to the top of pharma's TV spending list for February

AbbVie’s Humira is back—at the top of the pharma TV ad spending pile, that is. In February, Humira was the No. 1 spender again, according to data from real-time TV ad tracker iSpot.tv, swapping places with Pfizer’s Xeljanz.

Pfizer has been spending more heavily to tout Xeljanz’ indication for ulcerative colitis with a TV ad that launched in December. It has spent more than $80 million in national TV media buys on that commercial since it began, according to iSpot data.

One newcomer to the list, Eli Lilly migraine drug Emgality, made the top 10 on the media-spending strength of its debut campaign, in which a mom who suffers from migraines enjoys an imagination-filled day with her young daughter. Gilead’s Truvada rejoined the list in February with its straight-talking "Honestly" PrEP campaign for HIV prevention that began last summer. Otsuka and Lundbeck’s antipsychotic also landed back in the top 10 with Rexulti’s latest TV commercial debut that continues the series of ads in which patients hold up smiley face masks to hide their symptoms of depression.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.